论文部分内容阅读
检测和分析了７３例各类肾脏疾病患者和对照组人群的血脂、载脂蛋白、血清和尿液中ＬＰ（ａ）水平，表明各类肾小球疾病及慢性肾衰、糖尿病肾病患者具脂质代谢异常，血清高浓度Ｌｐ（ａ）为其另一生化特征。血清Ｌｐ（ａ）同血清白蛋白、尿总蛋白及尿蛋白分子大小均显著相关；尿Ｌｐ（ａ）排泄减少，且同血清肌酐水平相关。对肾脏病患 者Ｌｐ（ａ）的代谢特点进行了初步探讨，认为高Ｌｐ（ａ）血症不仅是肾脏病患者脂代谢的异常表现，可能同时参与了肾脏病的本身进展。
The levels of LP (a) in blood lipids, apolipoproteins, serum and urine of 73 patients with various types of renal diseases and controls were detected and analyzed. The results showed that all kinds of glomerular diseases and chronic renal failure, and patients with diabetic nephropathy had lipid Metabolic abnormalities, high concentrations of serum Lp (a) for the other biochemical characteristics. Serum Lp (a) was significantly associated with serum albumin, urinary total protein and urinary protein molecular size; urinary Lp (a) excretion decreased, and serum creatinine levels. Metabolic characteristics of Lp (a) in patients with kidney disease were preliminarily discussed. It is considered that hyperlipidemia is not only an abnormal manifestation of lipid metabolism in patients with kidney disease, but also may be involved in the progression of nephropathy.